PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

PROCEPT BioRobotics Corporation

Cyber Surgery develops innovative robotic assistants for seamless spinal procedures, focusing on surgical planning and vertebral fusion.

Cyber Surgery

Integrated Surgical is a Service-Disabled Veteran Owned Small Business that specializes in federal healthcare supply chain and contracting expertise, combining clinical sales and marketing.

Integrated Surgical

The Robot Report provides news, insights, and analysis on robotics and automation. It covers various technologies, market trends, and financial aspects related to the robotics industry, self-described as a resource for the robotics community.

The Robot Report

PROCEPT BioRobotics develops and manufactures the AquaBeam Robotic System for aquablation therapy, a treatment for benign prostatic hyperplasia (BPH).

PROCEPT BioRobotics

PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. Our proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience.

Armentum Partners

CIBC Innovation Banking

Novo Holdings

Perceptive Advisors

Viking Global Investors

CPMG

T. Rowe Price

Duquesne Family Office

Fidelity

Fidelity Management and Research Company

Say hello to Barry Templin, a rockstar on our executive leadership team! With over 20 years of experience in clinical research, engineering, and market development, Barry’s expertise is transforming patient care.

From leading the game-changing PROSPECT study at Abbott Vascular to driving innovation at CardioKinetix, Barry’s journey has been nothing short of impressive. He started in engineering at GE Aircraft Engines and Guidant, and then transitioned to key clinical roles at Guidant and Abbott.

Barry holds a BS in Mechanical Engineering from Rose-Hulman Institute of Technology, and an MBA from Duke. 

We’re lucky to have Barry’s talent and passion fueling our mission to innovate and improve lives.

#Leadership #MedicalDevices

When Ed began experiencing #BPH symptoms, he was told, "Welcome to the club," but had no desire to be a part of it. 

Thanks to #Aquablation therapy, he experienced immediate and lasting symptom relief. https://bit.ly/3tFJM6X

Not all patients will experience the same results

Aquablation therapy now has 5-year results from two pivotal studies that demonstrate the reproducibility of Aquablation therapy to deliver significant symptom relief while preserving sexual function no matter the size of the patient’s prostate,” said Sham Shiblaq, EVP and Chief Commercial Officer of PROCEPT BioRobotics.
These impressive results are further validated by the growing number of hospitals and surgeons adopting Aquablation as their new standard of care for BPH treatment. Discover the advantages of #AquablationTherapy for managing #BPH patients. Explore the Five-Year data from the WATER II study: https://lnkd.in/dFBwzBfJ
#ClinicalStudy #BPHTreatment

Ever wondered why your fellow urologists are raving about Aquablation therapy? 
Catch Episode 103 of the Prostate Health Podcast! Dr. Jennifer E. Lloyd-Harris dives deep into why she chose to adopt this groundbreaking robotic waterjet technology in her practice. 
Discover what makes Aquablation therapy a game-changer for BPH treatment and why you should consider offering it to your patients.
#ProstateHealthPodcast #AquablationTherapy 
https://bit.ly/4cCXzN0

Ever wondered what’s going on with your plumbing? A normal prostate lets urine flow smoothly, but an enlarged prostate can turn that into a tricky business. 
Think of benign prostatic hyperplasia (BPH) as a friendly but overgrown neighbor—it’s not cancer, but it can cause some serious blockages! Left unchecked, it might lead to bladder or kidney issues.
#ProstateHealth #BPH

Metric
Company Name	PROCEPT BioRobotics Corporation	Cyber Surgery	Integrated Surgical	The Robot Report
Symbol	PRCT
MSH ID	COM:PROCEPT-BIOROBOTICS	COM:CYBER-SURGERY	COM:INTEGRATEDSURG	COM:THEROBOTREPORT
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Technology
Industry	Medical - Devices	Medical Devices	Medical Equipment and Supplies	Robotics
Country	US	ES	US	US
Stage		Non Equity Assistance
Employee Count	626
Website	procept-biorobotics.com	cyber-surgery.com	integratedsurg.com	therobotreport.com
LinkedIn	procept-corporation	cyber-surgery
Founders

Metric
Market Cap	3.35B
Enterprise Value
Monthly Web Traffic		463	973	310.25K
Web Traffic Growth			12.51	0.07
Valuation
Raised Capital

Metric
Revenue	136.19M
Revenue (LTM)
Revenue (NTM)
Gross Profit	71.05M
EBITDA	-105.36M
Operating Income	-109.17M
Net Income	-105.90M
EPS	-2.24
Diluted EPS	-2.24
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.53
Operating Profit Margin	-0.62
EBITDA Margin	-0.77
Net Profit Margin	-0.59
Return on Equity	-0.38
Return on Assets	-0.26
Return on Capital Employed	-0.30

COM:PROCEPT-BIOROBOTICS

PROCEPT BioRobotics

Last Close

69.27

14/02 21:00

Market Cap

3.35B

Beta: -

Volume Today

751.65K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-21.41
P/B Ratio	7.79
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	25.00
EV Multiple	-24.99

Metric
Days Sales Outstanding	108.58
Days Payables Outstanding	88.75
Days Inventory Outstanding	218.34
Operating Cycle	347.99
Cash Conversion Cycle	286.39
Asset Turnover	0.47

Metric
Operating Cash Flow	-108.00M
Free Cash Flow	-133.21M
Cash Flow to Debt	-1.31
Operating Cash Flow/Sales	-0.52
Free Cash Flow Yield	-0.05

Metric
Cash & Equivalents	257.22M
Accounts Receivable	-33.10M
Inventory	39.76M
Goodwill
Debt to Capitalization	0.23
Debt to Assets	0.19
Current Ratio	8.91
Quick Ratio	7.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.15
R&D to Revenue	0.37
SG&A to Revenue